816284--2/20/2008--CELGENE_CORP

related topics

{product, liability, claim}

{product, candidate, development}

{product, market, service}

{stock, price, share}

{regulation, government, change}

{personnel, key, retain}

{property, intellectual, protect}

{investment, property, distribution}

{provision, law, control}

{financial, litigation, operation}

{operation, international, foreign}

{tax, income, asset}

{control, financial, internal}

{acquisition, growth, future}

If our products are not accepted by the market, demand for our products will deteriorate or not materialize at all. We have grown rapidly, and if we fail to adequately manage that growth our business could be adversely impacted. If the third parties upon whom we rely fail to produce on a timely basis the encapsulation, finishing and packaging services in the volumes that we require or fail to meet quality standards and maintain necessary licensure from regulatory authorities, we may be unable to meet demand for our products, potentially resulting in lost revenues. We are in the process of establishing foreign marketing and distribution capabilities. We have entered into a definitive agreement to acquire Pharmion, subject to certain closing conditions, including the appropriate affirmative vote of Pharmion stockholders. The integration of Pharmion and other acquired businesses may present significant challenges to us. We may be unable to retain skilled personnel and maintain key relationships. The hazardous materials we use in our research, development and other business operations could result in significant liabilities, which could exceed our insurance coverage and financial resources. The pharmaceutical industry is subject to extensive government regulation which presents numerous risks to us. We may not be able to protect our intellectual property and our products may be subject to generic competition. Litigation on a variety of matters may subject us to significant legal expenses and liability. The pharmaceutical and biotech industry is highly competitive and subject to rapid and significant technological change. Sales of our products are dependent on third-party reimbursement. Changes in our effective income tax rate could impact our earnings. Our operations may be impacted by currency fluctuations that may cause our earnings to fluctuate. We may experience an adverse market reaction if we are unable to meet our financial reporting obligations. The price of our common stock may fluctuate significantly, which may make it difficult for you to sell the common stock when you want or at prices you find attractive. The number of shares of our common stock eligible for future sale could adversely affect the market price of our common stock. Our shareholder rights plan and certain charter and by-law provisions may deter a third-party from acquiring us and may impede the stockholders ability to remove and replace our management or board of directors.

Full 10-K form ▸

816284--2/20/2008--CELGENE_CORP_/DE/